Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
ID: 357250Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357250

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-034.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Chemical Countermeasures Research Program (CCRP) Initiative, aimed at supporting research on the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids, such as fentanyl and carfentanil. This initiative seeks to advance understanding of both immediate and delayed health impacts associated with these substances, emphasizing innovative research into toxicity mechanisms and the development of new therapeutic strategies. The program will provide up to four grants, with a maximum award of $300,000 annually over a potential five-year period, totaling an estimated $2 million in funding. Interested applicants, including various educational and nonprofit institutions, must submit their proposals by November 18, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-26-034-Full-Announcement.html
    RFA-DA-26-034.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Chemical Countermeasures Research Program (CCRP) Initiative which aims to support research into the harmful effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids like fentanyl and carfentanil. The funding opportunity (RFA-DA-26-034) emphasizes understanding the immediate and delayed health impacts of these chemicals, which have been classified as high-consequence due to their danger in both public health and potential military applications. The initiative seeks innovative research focusing on mechanisms of toxicity, historical knowledge gaps regarding molecular effects, and the development of new therapeutic strategies. Grants will provide up to four awards totaling $2 million for projects not exceeding $300,000 annually over a potential five-year period. Eligibility includes a wide range of institutions, such as higher education and nonprofit organizations, but excludes foreign entities. Applications must avoid focusing solely on traditional opioid mechanisms and must propose pathways for innovative drug discovery aimed at UPS opioid exposure. The announcement includes specific application guidelines and deadlines, with an aim to advance the understanding and mitigation of opioid-related health crises.
    Similar Opportunities
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System." This initiative invites applications for basic research projects focused on understanding the mechanisms of toxicity of chemical warfare agents and toxic industrial chemicals that impact the nervous system, with the aim of developing potential therapeutic countermeasures for civilian exposure. The program is particularly significant in enhancing public health responses to chemical threats, emphasizing innovative and transdisciplinary research approaches. Up to four grants totaling $2 million are anticipated for fiscal year 2026, with applications due by 5 PM local time on October 17, 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis" (RFA-DA-23-054), aimed at supporting innovative research that bridges the gap between research findings and practical applications to combat the opioid overdose crisis. This initiative emphasizes the need for stigma-free, patient-centered care systems and focuses on understudied areas related to overdose prevention, requiring applicants to present preliminary data for significant projects within a maximum project period of five years and a budget of up to $750,000 in direct costs annually. The funding reflects a commitment to addressing health disparities and promoting effective addiction treatment and recovery solutions, with applications evaluated based on significance, innovation, feasibility, and stakeholder engagement. Interested applicants should note that the application deadline is March 20, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis," aimed at supporting research that translates findings into practical solutions for addressing the overdose crisis. This initiative encourages applications from a diverse range of organizations, including educational institutions and nonprofits, with a focus on developing stigma-free, patient-centered systems for addiction recovery and improving the quality of addiction treatment services. The NIH plans to commit approximately $10 million to fund grants, with an expected award ceiling of $750,000 for up to 12 awards, and applications will be accepted starting February 20, 2025, with a closing date of March 20, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-077.html.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)." This initiative invites Small Business Technology Transfer (STTR) grant applications from small business concerns proposing research projects aimed at developing innovative, FDA-regulated medical products to address the urgent needs of patients suffering from opioid and stimulant use disorders. The program is particularly focused on two scientific areas: pharmacotherapeutics and medical therapeutic and diagnostic devices, including software as a medical device, in response to the national crisis of substance use disorders. Grants of up to $300,000 are available, with a submission deadline of February 14, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.